Abstract 4278
Background
Specific anatomical locations of melanoma mets (MM) influence OS in pts treated with anti-PD-1 based immunotherapy (IT), but little is known about anatomical distribution of mets within a patient (patterns of MM). We investigated the clinical factors and OS associated with the patterns of MM.
Methods
Demographics, disease characteristics and patient outcomes were examined from MM pts. Univariate and multivariable (MVA) logistic regression was used to identify factors associated with patterns of MM. Cox proportional hazards method for OS analysis.
Results
6031 MM pts were studied; median age of 61yo, 66% male, 32% elevated LDH, 74% stage IV M1c/d. 17% had systemic treatment; IT (61%), targeted therapy (32%) and chemotherapy (7%) 1st line. Median FU was 57.5 months (mos) and the median OS (mOS) was 9.4 mos (untreated: 7.5 mos; treated: 39.4 mos). In MVA performed on untreated pts, elevated LDH (HR 1.5) and presence of brain (HR 1.5), liver (HR 1.8) and bone (HR 1.5) mets were associated with shorter OS; while gastrointestinal (GI) mets (HR 0.8) were associated with longer OS. Similar results were found for treated pts; but male pts had shorter OS (HR 1.3) and GI mets did not affect OS. Within all pts, mOS for pts with vs without brain mets was 8 vs 10 mos (p < 0.01), respectively; and mOS for pts with vs without liver mets was 7 vs 11 mos (p < 0.01), respectively. In untreated pts, brain mets were associated with adrenal mets, but not liver, GI, bone or subcutaneous (subcut); while in treated pts brain mets were associated with adrenal and subcut mets. Liver mets occurred frequently with bone, adrenal and spleen mets, and less frequently with brain, GI and subcut mets in untreated pts; while they were associated with bone and spleen mets in treated pts. Untreated pts with brain, liver or bone mets had longer mOS in the presence of GI mets (7 vs 11; 6 vs 8; 7 vs 11mos, respectively), while GI mets did not affect OS in treated pts. Treated pts with liver mets have shorter OS (22 mos) if bone (18 mos), adrenal (14 mos) or spleen (18 mos) mets are present, but this was not seen in untreated pts.
Conclusions
Both treated and untreated pts have distinct patterns of MM and survival. These data may help defining prognosis and provides insight to further studies on the biology of mets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melanoma Institute Australia.
Funding
Has not received any funding.
Disclosure
M.S. Carlino: Advisory / Consultancy: MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: Amgen; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Mass-Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche; Advisory / Consultancy: Aduro. All other authors have declared no conflicts of interest.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract